Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: TG4001

Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers

20210310 Transgene TG4001 randomized Phase II EN

Published 10 March 2021
Categorized as 2021, Press release, TG4001, TG4001

Transgene to present Phase 1b/2 trial results of TG4001 in combination with avelumab in advanced HPV-positive cancers at ESMO IO 2020

20201203 – TG4001 mini oral prez ESMO IO EN

Published 3 December 2020
Categorized as 2020, Press release, TG4001, TG4001

Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020

20201109 – TG4001+avelumab presentation poster SITC – EN

Published 9 November 2020
Categorized as 2020, Press release, TG4001, TG4001

Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers

20201027 – TG4001+avelumab abstract data SITC – EN

Published 27 October 2020
Categorized as 2020, Press release, TG4001, TG4001

Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on the detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers

20201019 TG4001+avelumab SITC – EN

Published 19 October 2020
Categorized as 2020, Press release, TG4001, TG4001

Transgene Reports Results from Clinical Study of TG4001 in Combination with Avelumab in Advanced HPV-Positive Cancers

CP TG4001+avelumab EN – Vdef-

Published 22 July 2020
Categorized as 2020, Press release, TG4001, TG4001

Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers

Christophe Le Tourneau et al. ESMO 2019 Download the poster here Poster Presentation

Published 30 September 2019
Categorized as -others, 2018, 2019, Publication, TG4001, TG4001, TG6002 (FR)

Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019

20190930 PR TG4001 ESMO EN

Published 30 September 2019
Categorized as 2019, Press release, TG4001, TG4001

Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers

C. Le Tourneau, et al.European Journal of Cancer, July 2023 (191)Access the article herePublication

Published 30 September 2019
Categorized as -others, 2023, Publication, TG4001, TG4001

Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers

Christophe Le Tourneau et al.ESMO 2019Download the poster herePoster Presentation

Published 27 September 2019
Categorized as -others, 2019, 2025, Publication, publication key en, TG4001, TG4001, TG4050

Posts pagination

Newer posts Page 1 Page 2 Page 3 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu